The Haemato‐Oncology Frailty (HOF) score to assess frailty in lymphoma
Morbidity and mortality during chemotherapy in older adults with haematological malignancy can be unpredictable. The Haemato‐Oncology Frailty (HOF) score was previously found to predict outcomes in a cohort of patients with plasma cell myeloma. In this study, we assess its utility in assessing frail...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2024-04, Vol.112 (4), p.611-620 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 620 |
|---|---|
| container_issue | 4 |
| container_start_page | 611 |
| container_title | European journal of haematology |
| container_volume | 112 |
| creator | Ramdany, Hena Lofaro, Thomas Deplano, Simona |
| description | Morbidity and mortality during chemotherapy in older adults with haematological malignancy can be unpredictable. The Haemato‐Oncology Frailty (HOF) score was previously found to predict outcomes in a cohort of patients with plasma cell myeloma. In this study, we assess its utility in assessing frailty in patients with lymphoma, and compare its performance to that of two other frailty scores. The HOF score was able to predict progression‐free survival in this population, and was also shown to have potential in assessing the dynamism of frailty during chemotherapy. It performed well when compared to the Charlson Comorbidity Index (CCI) score and the Haematopoietic Cell Transplantation‐Specific Comorbidity Index (HCTCI), although the study was not powered to assess for non‐inferiority. The HOF score is a new score with the potential for application in different haematological malignancies. |
| doi_str_mv | 10.1111/ejh.14152 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2904158129</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2904158129</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3532-7fc2683f4bd31aef22ae941bdd7767a136109019e6d70094c6ffede74e543ef73</originalsourceid><addsrcrecordid>eNp10L9OwzAQBnALgWgpDLwAisTSDmn9r3E8oqolIKQuZbbc5ExTJXGJU6FsPALPyJPgksKAxC033E-fTh9C1wSPiZ8JbDdjwsmUnqA-iTAOcYTlKepjiWnIOSc9dOHcFmNMJRHnqMdiQijloo-S1QaCREOpG_v5_rGsUlvYlzZY1DovmjYYJsvFKHCprSFobKCdA-cCc7zmVVC05W5jS32JzowuHFwd9wA9L-arWRI-Le8fZndPYcqmjIbCpDSKmeHrjBENhlINkpN1lgkRCU1YRPzXREKUCYwlTyNjIAPBYcoZGMEGaNjl7mr7ugfXqDJ3KRSFrsDunaIS-yZiQqWnt3_o1u7ryn_nlScxj-VBjTqV1ta5Goza1Xmp61YRrA71Kl-v-q7X25tj4n5dQvYrf_r0YNKBt7yA9v8kNX9Musgvn7WClg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2958184899</pqid></control><display><type>article</type><title>The Haemato‐Oncology Frailty (HOF) score to assess frailty in lymphoma</title><source>Wiley-Blackwell Journals</source><creator>Ramdany, Hena ; Lofaro, Thomas ; Deplano, Simona</creator><creatorcontrib>Ramdany, Hena ; Lofaro, Thomas ; Deplano, Simona</creatorcontrib><description>Morbidity and mortality during chemotherapy in older adults with haematological malignancy can be unpredictable. The Haemato‐Oncology Frailty (HOF) score was previously found to predict outcomes in a cohort of patients with plasma cell myeloma. In this study, we assess its utility in assessing frailty in patients with lymphoma, and compare its performance to that of two other frailty scores. The HOF score was able to predict progression‐free survival in this population, and was also shown to have potential in assessing the dynamism of frailty during chemotherapy. It performed well when compared to the Charlson Comorbidity Index (CCI) score and the Haematopoietic Cell Transplantation‐Specific Comorbidity Index (HCTCI), although the study was not powered to assess for non‐inferiority. The HOF score is a new score with the potential for application in different haematological malignancies.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/ejh.14152</identifier><identifier>PMID: 38112247</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Chemotherapy ; Comorbidity ; frail elderly ; geriatric assessment ; Hematopoietic stem cells ; Lymphoma ; Malignancy ; Morbidity ; Myeloma ; older adults ; Oncology ; personalised medicine ; quality of life ; Transplantation</subject><ispartof>European journal of haematology, 2024-04, Vol.112 (4), p.611-620</ispartof><rights>2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3532-7fc2683f4bd31aef22ae941bdd7767a136109019e6d70094c6ffede74e543ef73</citedby><cites>FETCH-LOGICAL-c3532-7fc2683f4bd31aef22ae941bdd7767a136109019e6d70094c6ffede74e543ef73</cites><orcidid>0000-0003-1248-9192 ; 0000-0001-8127-5660</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fejh.14152$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fejh.14152$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38112247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramdany, Hena</creatorcontrib><creatorcontrib>Lofaro, Thomas</creatorcontrib><creatorcontrib>Deplano, Simona</creatorcontrib><title>The Haemato‐Oncology Frailty (HOF) score to assess frailty in lymphoma</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>Morbidity and mortality during chemotherapy in older adults with haematological malignancy can be unpredictable. The Haemato‐Oncology Frailty (HOF) score was previously found to predict outcomes in a cohort of patients with plasma cell myeloma. In this study, we assess its utility in assessing frailty in patients with lymphoma, and compare its performance to that of two other frailty scores. The HOF score was able to predict progression‐free survival in this population, and was also shown to have potential in assessing the dynamism of frailty during chemotherapy. It performed well when compared to the Charlson Comorbidity Index (CCI) score and the Haematopoietic Cell Transplantation‐Specific Comorbidity Index (HCTCI), although the study was not powered to assess for non‐inferiority. The HOF score is a new score with the potential for application in different haematological malignancies.</description><subject>Chemotherapy</subject><subject>Comorbidity</subject><subject>frail elderly</subject><subject>geriatric assessment</subject><subject>Hematopoietic stem cells</subject><subject>Lymphoma</subject><subject>Malignancy</subject><subject>Morbidity</subject><subject>Myeloma</subject><subject>older adults</subject><subject>Oncology</subject><subject>personalised medicine</subject><subject>quality of life</subject><subject>Transplantation</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp10L9OwzAQBnALgWgpDLwAisTSDmn9r3E8oqolIKQuZbbc5ExTJXGJU6FsPALPyJPgksKAxC033E-fTh9C1wSPiZ8JbDdjwsmUnqA-iTAOcYTlKepjiWnIOSc9dOHcFmNMJRHnqMdiQijloo-S1QaCREOpG_v5_rGsUlvYlzZY1DovmjYYJsvFKHCprSFobKCdA-cCc7zmVVC05W5jS32JzowuHFwd9wA9L-arWRI-Le8fZndPYcqmjIbCpDSKmeHrjBENhlINkpN1lgkRCU1YRPzXREKUCYwlTyNjIAPBYcoZGMEGaNjl7mr7ugfXqDJ3KRSFrsDunaIS-yZiQqWnt3_o1u7ryn_nlScxj-VBjTqV1ta5Goza1Xmp61YRrA71Kl-v-q7X25tj4n5dQvYrf_r0YNKBt7yA9v8kNX9Musgvn7WClg</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Ramdany, Hena</creator><creator>Lofaro, Thomas</creator><creator>Deplano, Simona</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1248-9192</orcidid><orcidid>https://orcid.org/0000-0001-8127-5660</orcidid></search><sort><creationdate>202404</creationdate><title>The Haemato‐Oncology Frailty (HOF) score to assess frailty in lymphoma</title><author>Ramdany, Hena ; Lofaro, Thomas ; Deplano, Simona</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3532-7fc2683f4bd31aef22ae941bdd7767a136109019e6d70094c6ffede74e543ef73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Chemotherapy</topic><topic>Comorbidity</topic><topic>frail elderly</topic><topic>geriatric assessment</topic><topic>Hematopoietic stem cells</topic><topic>Lymphoma</topic><topic>Malignancy</topic><topic>Morbidity</topic><topic>Myeloma</topic><topic>older adults</topic><topic>Oncology</topic><topic>personalised medicine</topic><topic>quality of life</topic><topic>Transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramdany, Hena</creatorcontrib><creatorcontrib>Lofaro, Thomas</creatorcontrib><creatorcontrib>Deplano, Simona</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramdany, Hena</au><au>Lofaro, Thomas</au><au>Deplano, Simona</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Haemato‐Oncology Frailty (HOF) score to assess frailty in lymphoma</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2024-04</date><risdate>2024</risdate><volume>112</volume><issue>4</issue><spage>611</spage><epage>620</epage><pages>611-620</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>Morbidity and mortality during chemotherapy in older adults with haematological malignancy can be unpredictable. The Haemato‐Oncology Frailty (HOF) score was previously found to predict outcomes in a cohort of patients with plasma cell myeloma. In this study, we assess its utility in assessing frailty in patients with lymphoma, and compare its performance to that of two other frailty scores. The HOF score was able to predict progression‐free survival in this population, and was also shown to have potential in assessing the dynamism of frailty during chemotherapy. It performed well when compared to the Charlson Comorbidity Index (CCI) score and the Haematopoietic Cell Transplantation‐Specific Comorbidity Index (HCTCI), although the study was not powered to assess for non‐inferiority. The HOF score is a new score with the potential for application in different haematological malignancies.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38112247</pmid><doi>10.1111/ejh.14152</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-1248-9192</orcidid><orcidid>https://orcid.org/0000-0001-8127-5660</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2024-04, Vol.112 (4), p.611-620 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2904158129 |
| source | Wiley-Blackwell Journals |
| subjects | Chemotherapy Comorbidity frail elderly geriatric assessment Hematopoietic stem cells Lymphoma Malignancy Morbidity Myeloma older adults Oncology personalised medicine quality of life Transplantation |
| title | The Haemato‐Oncology Frailty (HOF) score to assess frailty in lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T19%3A11%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Haemato%E2%80%90Oncology%20Frailty%20(HOF)%20score%20to%20assess%20frailty%20in%20lymphoma&rft.jtitle=European%20journal%20of%20haematology&rft.au=Ramdany,%20Hena&rft.date=2024-04&rft.volume=112&rft.issue=4&rft.spage=611&rft.epage=620&rft.pages=611-620&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/ejh.14152&rft_dat=%3Cproquest_cross%3E2904158129%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2958184899&rft_id=info:pmid/38112247&rfr_iscdi=true |